Amphastar Pharmaceuticals (AMPH) Non-Current Deferred Tax Liability (2013 - 2023)

Amphastar Pharmaceuticals' Non-Current Deferred Tax Liability history runs 11 years deep, the most recent figure standing at $201000.0 for Q3 2023.

• In Q3 2023, Non-Current Deferred Tax Liability fell 16.94% year-over-year to $201000.0; the TTM figure through Sep 2023 stood at $201000.0 (down 16.94% YoY), while the FY2022 annual figure was $144000.0, down 73.03% from the prior year.
• Non-Current Deferred Tax Liability was $201000.0 for Q3 2023 at Amphastar Pharmaceuticals, roughly flat from $201000.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $2.9 million in Q3 2021 to a low of $144000.0 in Q4 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $724222.2 across 5 years, with a median of $748000.0 in 2020.
• The sharpest annual moves came in 2021 and 2022: Non-Current Deferred Tax Liability surged 252.49% in 2021, then tumbled 91.66% in 2022.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $867000.0 in 2019, then declined by 14.53% to $741000.0 in 2020, then fell by 27.94% to $534000.0 in 2021, then sank by 73.03% to $144000.0 in 2022, then jumped by 39.58% to $201000.0 in 2023.
• The last three Non-Current Deferred Tax Liability figures came in at $201000.0 (Q3 2023), $201000.0 (Q2 2023), and $178000.0 (Q1 2023), per Business Quant data.